Tapan M. Kadia
University of Texas MD Anderson Cancer Center
1035 Papers
2.3K Citations
Tapan M. Kadia is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 52, co-authored 700 publications. Previous affiliations of Tapan M. Kadia include University of Perugia & University of Texas Health Science Center at Houston.
Chat about Author
Papers
•Journal Article
Treatment-free remission in chronic myeloid leukemia.
Matteo Molica,Kiran Naqvi,Jorge E. Cortes,Shilpa Paul,Tapan M. Kadia,Massimo Breccia,Hagop M. Kantarjian,Elias Jabbour +7 more
TL;DR: Practice guidelines for optimal patient selection and proper monitoring after discontinuation of TKIs are proposed outside of clinical trials, given the heterogeneity of results reported in clinical trials.
16
Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.
Naval Daver,Guillermo Garcia-Manero,Jorge E. Cortes,Sreyashi Basu,Farhad Ravandi,Tapan M. Kadia,Gautam Borthakur,Elias Jabbour,Courtney D. DiNardo,Naveen Pemmaraju,Mark Brandt,Sherry Pierce,Nawar Hussin,Steven M. Kornblau,Michael Andreeff,Marina Konopleva,Jing Ning,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +19 more
TL;DR: Lack of KIR-HLA class I interactions has been associated with NK-mediated antitumor efficacy in AML patients in remission upon Kir-mismatched haploidentical stem cell transp...
16
Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia
Farhad Ravandi,Naval Daver,Guillermo Garcia-Manero,Christopher B. Benton,Philip A. Thompson,Gautam Borthakur,Tapan M. Kadia,Prajwal Boddu,Yesid Alvarado,Elias Jabbour,Marina Konopleva,Koichi Takahashi,Steven M. Kornblau,Courtney D. DiNardo,Zeev Estrov,Wilmer Flores,Sreyashi Basu,James P. Allison,Padmanee Sharma,Sherry Pierce,Mark Brandt,Allison Pike,Jorge E. Cortes,Hagop M. Kantarjian +23 more
TL;DR: It is hypothesized that addition of nivolumab to an induction regimen of ara-C and idarubicin may prolong relapse-free survival (RFS) and overall survival (OS) and this study was designed to determine the feasibility of this combination.
16
Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study
Naval Daver,Guillermo Garcia-Manero,Sreyashi Basu,Jorge E. Cortes,Farhad Ravandi,Tapan M. Kadia,Marina Konopleva,Elias J. Jabbour,Courtney D. DiNardo,Rita Assi,Sherry Pierce,Yesid Alvarado,Zeev Estrov,Naveen Pemmaraju,Koichi Takahashi,Jing Ning,Graciela M. Nogueras González,Steven M. Kornblau,Mansour Alfayez,Jairo Matthews,Wilmer Flores,Jorge Blando,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +24 more
TL;DR: Improved OS was seen in pts who achieved any response or SD, and patients who achieved a CR/CRi/PR/HI/SD had significantly improved overall survival (OS) compared with NRs, which compared favorably to historical med OS with AZA-based protocols.
16
Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)
Naveen Pemmaraju,Bing Z. Carter,Hagop M. Kantarjian,Jorge E. Cortes,Tapan M. Kadia,Guillermo Garcia-Manero,Courtney D. DiNardo,Prithviraj Bose,Sherry Pierce,Lingsha Zhou,Zeev Estrov,Carla Tuttle,Karina Salinas,Po Yee Mak,Srdan Verstovsek +14 more
TL;DR: An investigator-initiated, single-center, phase II study of LCL161 as monotherapy for patients with intermediate or high risk myelofibrosis who have failed or are intolerant to Janus kinase (JAK) inhibitors such as ruxolitinib to determine efficacy.
16